(Table 2, Table 3 and Table 4) These results are consistent with previous studies that have demonstrated a predominance in the PI3K/Akt/mTOR and Ras/BRAF/Mek/Erk protein kinase pathways in molecularly targeted glioma treatment [5,6]. The gene discussed is MAP2K7; the disease is central nervous system cancer.